MLF2 Modulates USP7–p53 Axis to Drive Colorectal Carcinogenesis

Study Background and Research Question

The tumor suppressor p53 is a central regulator of cell cycle arrest, apoptosis, and cellular responses to stress, acting as a barrier against tumorigenesis in multiple tissues. However, in many human cancers, p53 activity is lost not only through gene mutation or deletion but also by disruption of its regulatory network. In colorectal cancer—a leading cause of cancer-related mortality globally—understanding the mechanisms of wild-type p53 inactivation is crucial for translational research and therapeutic innovation (Fang et al., 2023).

Ubiquitin-specific protease 7 (USP7) is known to stabilize both p53 and its negative regulator Mdm2 through deubiquitination, thereby intricately balancing p53 levels. Previous studies have established that USP7 dysregulation can profoundly affect p53-dependent tumor suppression. However, the landscape of endogenous modulators of USP7 activity in colorectal cancer remains incompletely mapped. The study by Fang et al. addresses whether myeloid leukemia factor 2 (MLF2) functions as a negative regulator of p53 and explores its role in colorectal tumorigenesis.

Key Innovation from the Reference Study

The central innovation of Fang et al. is the identification of MLF2 as a direct antagonist of p53 stability. The study demonstrates that MLF2 interacts with both p53 and USP7, physically blocking the USP7–p53 association required for p53 deubiquitination and stabilization. This disruption leads to enhanced ubiquitin-mediated p53 degradation and, consequently, attenuation of p53 tumor suppressor function (Fang et al., 2023).

This work not only characterizes MLF2 as an oncogenic factor in colorectal cancer but also adds a new dimension to our understanding of how wild-type p53 function can be compromised in tumors without direct genetic alterations of TP53. The elevation of MLF2 in clinical colorectal cancer samples and its correlation with poor patient prognosis further underscore its functional and translational relevance.

Methods and Experimental Design Insights

To dissect the role of MLF2, the authors employed a combination of molecular, cellular, and clinical approaches:

• Protein–protein interaction assays: Co-immunoprecipitation (Co-IP) experiments in human colorectal cancer cell lines established the physical interaction between MLF2, p53, and USP7.
• Protein stability and ubiquitination assays: Cycloheximide chase and ubiquitination assays quantified p53 turnover and polyubiquitin chain addition in the presence and absence of MLF2.
• Gene expression analyses: RNA and protein levels of MLF2 and p53 were measured in tumor and matched normal tissues to establish clinical correlation.
• Functional cell assays: Proliferation, apoptosis, and colony formation assays assessed the phenotypic consequences of MLF2 overexpression or knockdown.
• In vivo tumorigenicity: Xenograft models evaluated the impact of MLF2 on tumor growth in immunodeficient mice.

Throughout these workflows, the preservation of labile proteins, including p53, during extraction and analysis was essential to avoid confounding degradation artifacts, a challenge well-documented in advanced proteomics (internal article).

Protocol Parameters

• Western blotting | 1–5 μg protein/lane | detection of endogenous and overexpressed p53, MLF2, USP7 | Ensures accurate quantification of protein stability and modifications | paper
• Co-immunoprecipitation | 1–2 mg total protein/sample | mapping protein–protein interactions | High input required for robust detection of transient complexes | paper
• Protease inhibitor cocktail addition | 1:200 dilution of 200X stock | all protein extraction workflows | Prevents serine/cysteine/acid protease-mediated degradation of p53 and interacting partners | workflow_recommendation
• Culture medium exchange | every 48 h with fresh inhibitor-supplemented medium | long-term cell experiments | Maintains inhibitor efficacy during extended assays | product_spec

Core Findings and Why They Matter

Fang et al. found that MLF2 is upregulated in human colorectal cancers and its expression is inversely correlated with p53 levels in tumors harboring wild-type p53. Mechanistically, MLF2 antagonizes USP7-mediated p53 stabilization by preventing their physical association, resulting in increased polyubiquitination and proteasomal degradation of p53 (Fang et al., 2023).

Functionally, overexpression of MLF2 promoted proliferation and tumorigenicity in both in vitro and in vivo models, whereas MLF2 knockdown led to increased p53 stability, elevated apoptosis, and reduced clonogenic growth. Clinically, high MLF2 expression correlated with poorer survival outcomes, highlighting its potential as a prognostic biomarker and therapeutic target.

These findings clarify how wild-type p53 can be functionally suppressed in the absence of genetic mutations through regulatory protein networks. This has significant implications for designing strategies to reactivate p53 in p53-intact tumors and for interpreting experimental results where p53 stability is a critical readout.

Comparison with Existing Internal Articles

Internal resources such as "Protease Inhibitor Cocktail EDTA-Free (200X in DMSO): Mechanisms and Applications" and "Protease Inhibitor Cocktail EDTA-Free: Precision in Proteome Analysis" emphasize the importance of comprehensive protease inhibition, particularly in workflows sensitive to phosphorylation and protein–protein interaction mapping. These articles provide practical recommendations for using EDTA-free, serine protease inhibitor cocktails to avoid loss or modification of labile targets like p53 during Western blot and co-IP assays, as highlighted in the current study's methodology. The reference paper's rigorous control of protein degradation using such protocols reinforces the broader consensus that robust inhibitor application is indispensable for accurate mechanistic studies (internal article).

Limitations and Transferability

Despite the compelling mechanistic evidence, the study is limited by its focus on colorectal cancer models and its reliance on overexpression and knockdown systems, which may not fully recapitulate endogenous regulation in all tissue contexts. The cross-applicability of these findings to other cancer types, and to diverse regulatory landscapes of p53, remains to be validated.

Additionally, while rigorous protein extraction and preservation protocols were followed, experimental reproducibility in proteomics remains sensitive to subtle differences in sample handling. Thus, transferability of workflows requires careful adaptation and validation in each laboratory environment.

Research Support Resources

To support similar mechanistic investigations of p53 regulation or other labile protein networks, researchers may employ the Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) (SKU K1008) from APExBIO. This broad-spectrum, EDTA-free formulation contains serine, cysteine, and acid protease inhibitors, ensuring compatibility with phosphorylation-sensitive and co-immunoprecipitation workflows where preservation of protein stability is essential (product_spec). Application of such a protein extraction protease inhibitor can help prevent artifactual degradation and increase confidence in Western blot and interaction studies, as underscored by both the reference paper and internal workflow recommendations.